Related Experiment Videos
[Cytomegalovirus infection in neonate--report of two cases]
Abstract:
The cytomegalovirus (CMV) is an abiquitous agent that infects almost all human beings at some time during their lives. In developing area of the world, 90% or more of the population is infected during childhood. However, in developed countries the infection is acquired at a lower rate. In neonates, CMV infection can be divided into congenital and perinatal infection. Congenital CMV infection is the result of transplacental transmission, CMV can be transmitted to the fetus following reactivation as well as primary infection during pregnancy. The incidence of congenital infection is 0.2% to 2.2%. Symptomatic congenital CMV infection is more likely to be the result of primary as opposed to reactive CMV infection during pregnancy. The clinical manifestations of symptomatic CMV infection are hepatosplenomegaly, microcephaly, jaundice, petechiae, small for gestation age, periventricular calcification and chorioretinitis. Mortality may be as high as 30% among the most severely affected infants. In the survivors, about 90% will develop mild to severe handicaps. Perinatal CMV infection can be acquired from exposure to virus in the maternal genital tract at delivery, breast milk, or through blood transfusion. In premature infants who require prolonged and intensive medical care, blood transfusions are an important iatrogenic cause of CMV infection. Transfusion-acquired perinatal CMV infection can cause significant morbidity and mortality, particularly in premature infants with a birth weight of less than 1250 gm born to CMV-seronegative mothers. So CMV acquisition can be prevented either by providing these infants blood products from seronegative donors or by using frozen deglycerolized red blood cells. Two cases of neonatal CMV infection are reported, one with congenital infection, the other with perinatal infection.
Insights
Cytomegalovirus (CMV) infection in newborns can be congenital or perinatal. Congenital CMV, from maternal transmission, causes severe handicaps in survivors, while perinatal CMV, often from transfusions in premature infants, poses significant risks.
Area of Science:
- Virology
- Neonatal Medicine
- Infectious Diseases
Background:
- Cytomegalovirus (CMV) is a widespread human herpesvirus.
- Neonatal CMV infection presents as either congenital (transplacental) or perinatal (postnatal) acquisition.
- Congenital CMV infection occurs in 0.2%-2.2% of births, with primary maternal infection posing higher risk.
Observation:
- Symptomatic congenital CMV manifests with hepatosplenomegaly, microcephaly, jaundice, and developmental issues.
- Mortality in severely affected infants can reach 30%, with 90% of survivors experiencing handicaps.
- Perinatal CMV, particularly transfusion-acquired in premature infants, leads to significant morbidity and mortality.
Findings:
- Primary maternal CMV infection during pregnancy increases the risk of symptomatic congenital CMV.
- Premature infants born to CMV-seronegative mothers are highly vulnerable to transfusion-acquired CMV.
- Preventive strategies include using CMV-seronegative blood products or processed red blood cells.
Implications:
- Early identification and management of neonatal CMV are crucial for improving outcomes.
- Preventing transfusion-acquired CMV in vulnerable neonates can reduce mortality and long-term complications.
- Understanding transmission routes informs public health strategies for CMV control.